Pharmaxis Ltd., of Sydney, reported that the National Health and Medical Research Council has awarded it a research grant of A$421,545 (US$318,560) for development and testing of its Orbital Inhaler with a dry powder formulation of the antibiotic tobramycin for the treatment of cystic fibrosis. The company will work with the Sydney-based Woolcock Institute of Medical Research.